Overview

A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Status:
Completed
Trial end date:
2019-04-10
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy on abdominal symptoms (abdominal bloating, abdominal discomfort, and abdominal pain) and safety of linaclotide 290 μg administered orally to patients with IBS-C.
Phase:
Phase 3
Details
Lead Sponsor:
Ironwood Pharmaceuticals, Inc.
Collaborator:
Allergan Sales, LLC
Treatments:
Linaclotide